Brotizolam
A thienodiazepine drug with sedative, hypnotic, and anxiolytic properties, used in some countries for the short-term treatment of insomnia and anxiety. It acts on GABA-A receptors similarly to benzodiazepines to promote sleep and reduce anxiety. Risk of tolerance, dependence, and withdrawal limits its use to short-term treatment.
Molekularmasse
393,7000 g/mol
LogP
2,80
TPSA
71,30 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …
2D-Struktur
Cite this structure
Embed this structure
SMILES
Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2
InChI
InChI=1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3
Molecular Formula
C15H10BrClN4S
HBD / HBA
- / 4
Rotierbare Bindungen
1
Schwere Atome
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A thienodiazepine drug with sedative, hypnotic, and anxiolytic properties, used in some countries for the short-term treatment of insomnia and anxiety. It acts on GABA-A receptors similarly to benzodiazepines to promote sleep and reduce anxiety. Risk of tolerance, dependence, and withdrawal limits its use to short-term treatment.
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Yes, Brotizolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL32479. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2451. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="brotizolam"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/brotizolam/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/brotizolam/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/brotizolam/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="brotizolam"></drugfyi-drug>